
NYSE:PG
This summary was created by AI, based on 11 opinions in the last 12 months.
Procter & Gamble (PG) is currently facing challenges in a difficult economy, leading to mixed views among experts. There is a general sentiment that while the company has strong brands and a stable dividend, growth may be limited due to inflation and rising input costs. Some analysts note that PG's stock had a significant drop over the past year, but it has potential for recovery, especially given its status as a dividend aristocrat. Concerns linger about consumer demand, with suggestions to enter the stock gradually as it may continue to struggle. Overall, despite short-term challenges, PG is viewed as a defensive investment.
PG vs. JNJ JNJ valuation of 16-17x earnings is cheaper than PG. JNJ has 3 areas: medical devices, healthcare, pharma. PG is just consumer products, trading at 23x earnings. More opportunity in JNJ, with a caveat on the talc lawsuits. JNJ's medical device side should do well post-Covid. Dividends similar in the 2.5% range.
He owns Unilever for their global exposure. P&G beat earnings but their revenues were down. It's trading like a growth stock even though it isn't. They have been coming out with new products. There is progress in grooming products but their baby care has been struggling. He also doesn't like their compliance and ethics. They reward 10% of their float to their executives and not helping employees. They are also make polluting products like Pampers and Swiffers.